CN102595884B - 认知衰退的抑制剂 - Google Patents

认知衰退的抑制剂 Download PDF

Info

Publication number
CN102595884B
CN102595884B CN201080043697.0A CN201080043697A CN102595884B CN 102595884 B CN102595884 B CN 102595884B CN 201080043697 A CN201080043697 A CN 201080043697A CN 102595884 B CN102595884 B CN 102595884B
Authority
CN
China
Prior art keywords
compound
acceptable salt
compounds
amyloid
pharmacy acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080043697.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102595884A (zh
Inventor
G·M·里什顿
S·卡塔拉诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognition Therapeutics Inc
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of CN102595884A publication Critical patent/CN102595884A/zh
Application granted granted Critical
Publication of CN102595884B publication Critical patent/CN102595884B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/25—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
    • C07C33/30—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/18—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080043697.0A 2009-07-31 2010-08-02 认知衰退的抑制剂 Expired - Fee Related CN102595884B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23032609P 2009-07-31 2009-07-31
US61/230,326 2009-07-31
US30868610P 2010-02-26 2010-02-26
US61/308,686 2010-02-26
PCT/US2010/044136 WO2011014880A1 (en) 2009-07-31 2010-08-02 Inhibitors of cognitive decline

Publications (2)

Publication Number Publication Date
CN102595884A CN102595884A (zh) 2012-07-18
CN102595884B true CN102595884B (zh) 2014-12-03

Family

ID=43529740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080043697.0A Expired - Fee Related CN102595884B (zh) 2009-07-31 2010-08-02 认知衰退的抑制剂

Country Status (12)

Country Link
US (2) US9192585B2 (https=)
EP (1) EP2458983B1 (https=)
JP (1) JP2013501006A (https=)
CN (1) CN102595884B (https=)
AU (2) AU2010278711A1 (https=)
BR (1) BR112012002246A2 (https=)
DK (1) DK2458983T3 (https=)
ES (1) ES2547730T3 (https=)
IL (1) IL217833A0 (https=)
RU (1) RU2012107457A (https=)
SG (2) SG10201506978UA (https=)
WO (1) WO2011014880A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10207991B2 (en) 2014-01-31 2019-02-19 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
CN102595884B (zh) * 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 认知衰退的抑制剂
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
BR112013019775A2 (pt) * 2011-02-02 2017-04-18 Cognition Therapeutics Inc composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
RU2599835C2 (ru) * 2011-03-29 2016-10-20 Каунсил Оф Сайнтифик Энд Индастриал Рисерч Способ модификации эфирного масла curcuma aromatica
GB201111319D0 (en) 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
EP2747768A4 (en) * 2011-08-25 2015-10-21 Cognition Therapeutics Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2747759A4 (en) * 2011-08-25 2015-05-13 Cognition Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991814B2 (en) * 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
IL70813A (en) 1983-01-31 1987-10-30 Lilly Co Eli Animal feed comprising certain phenethanolamine derivatives and 1-phenyl-2-(1-methyl-3-(4-nitrophenyl)propylamino)ethanol hydrochloride
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
ES2285707T3 (es) 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
JP3522930B2 (ja) * 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
WO1997040051A1 (en) 1996-04-24 1997-10-30 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
US20030073681A1 (en) 2001-08-21 2003-04-17 Hauske James R. 2-substituted piperidines that are ligands for monoamine receptors and transporters
EP1453528B1 (en) 2001-12-14 2009-07-22 Council of Scientific and Industrial Research Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
EP1644026A4 (en) 2003-06-12 2007-10-24 Ms Science Corp SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION
CZ2006628A3 (cs) 2004-03-12 2007-01-24 Egis Gyogyszergyár Nyrt. Kombinovaná farmaceutická kompozice pro inhibici poklesu kognitivních funkcí
TW200538052A (en) * 2004-05-31 2005-12-01 Kaneka Corp Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component
EP1794313B1 (en) 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006027252A1 (en) 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
WO2006094724A2 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
KR20080041624A (ko) 2005-06-15 2008-05-13 대릭 에스. 에치. 엘. 김 베타-아밀로이드 단백질-유발 안질환의 치료 방법
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
KR20090007564A (ko) * 2006-03-17 2009-01-19 허발사이언스 싱가포르 피티이 리미티드 쿠르쿠마 종을 포함한 추출물 및 이를 수득하는 방법
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
WO2008042755A2 (en) 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
CA2684920A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of treating cognitive disorders by inhibition of gpr12
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009059214A1 (en) 2007-11-02 2009-05-07 The Regents Of The University Of California Abeta-binding small molecules
EP2138104A1 (en) 2008-06-25 2009-12-30 Vibra Tech AB Core biopsy arrangement
WO2010062260A1 (en) 2008-11-29 2010-06-03 The Thailand Research Fund Virus and target cell interaction inhibition
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
AU2010226726B8 (en) 2009-03-16 2014-08-14 Pangu Biopharma Limited Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
CN102595884B (zh) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 认知衰退的抑制剂
WO2011106785A2 (en) 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
EP2747759A4 (en) 2011-08-25 2015-05-13 Cognition Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991814B2 (en) * 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10207991B2 (en) 2014-01-31 2019-02-19 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease

Also Published As

Publication number Publication date
IL217833A0 (en) 2012-03-29
US9815770B2 (en) 2017-11-14
ES2547730T3 (es) 2015-10-08
BR112012002246A2 (pt) 2019-09-24
AU2015242947A1 (en) 2015-10-29
JP2013501006A (ja) 2013-01-10
EP2458983B1 (en) 2015-07-08
EP2458983A4 (en) 2012-12-19
US20120129945A1 (en) 2012-05-24
DK2458983T3 (en) 2015-10-05
CN102595884A (zh) 2012-07-18
WO2011014880A1 (en) 2011-02-03
EP2458983A1 (en) 2012-06-06
SG178191A1 (en) 2012-03-29
US20160137588A1 (en) 2016-05-19
SG10201506978UA (en) 2015-10-29
AU2010278711A1 (en) 2012-02-23
RU2012107457A (ru) 2013-09-10
HK1171624A1 (en) 2013-04-05
AU2015242947B2 (en) 2017-09-28
US9192585B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
CN102595884B (zh) 认知衰退的抑制剂
EP2416795B1 (en) Inhibitors of cognitive decline
CN103458885B (zh) 由姜黄油分离的化合物及使用方法
US20170049723A1 (en) Isolated compounds from turmeric oil and methods of use
HK1171624B (en) Inhibitors of cognitive decline
HK1167323B (en) Inhibitors of cognitive decline

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141203